<DOC>
	<DOCNO>NCT00777348</DOCNO>
	<brief_summary>This multicentre , randomise , double-blind , placebo-controlled , 4-way cross-over study . At study visit standardise treadmill test perform provoke EIA . Before challenge test pulmonary function variable ( e.g . forced expiratory volume one second ( FEV1 ) ) measure order ass protective effect study medication .</brief_summary>
	<brief_title>To Assess Protective Effect Fixed Drug Combination Disodium Cromoglycate Plus Reproterol</brief_title>
	<detailed_description>- Primary objective : demonstrate superiority protective effect fix combination disodium cromoglycate ( DSCG ) plus reproterol comparison single component reproterol adult suffer exercise induce asthma ( EIA ) . - Secondary objective : demonstrate superiority protective effect DSCG plus reproterol comparison single component DSCG ; demonstrate superiority protective effect single component comparison placebo . In addition , tolerability medication document .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Asthma , Exercise-Induced</mesh_term>
	<mesh_term>Reproterol</mesh_term>
	<mesh_term>Metaproterenol</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<mesh_term>Cromolyn Sodium</mesh_term>
	<criteria>Female male subject age 18 65 year Exercise induce asthma reversible airway obstruction : twice proven EIA define maximum decrease FEV1 baseline value least 20 % ( first test result obtain last 12 month ) Baseline FEV1 challenge must &gt; = 70 % predict FEV1 Safety concern : Subjects hypersensitivity DSCG , reproterol , menthol , peppermint excipients study medication Pregnancy , breastfeed plan pregnancy study . Women child bear potential use highly effective method birth control define result low failure rate ( i.e . &lt; 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , hormonal IUDs , tubal ligation vasectomise partner Subjects asthma exacerbation within 4 week prior study start . Asthma exacerbation define use oral ( systemic ) glucocorticosteroids , unscheduled consultation medic due asthma , hospitalisation , additional treatment asthma antibiotic Eosinophilic pneumonia Clinically significant cardiovascular disease ( e.g . cardiac infarction , cardiac dysrhythmia , hypertrophic obstructive cardiomyopathy , coronary heart disease… ) Resting blood pressure 140/90 mmHg Diastolic blood pressure treadmilltest 120 mmHg Malignancies include phaeochromocytoma within last 5 year Severe hyperthyreosis , thyreotoxicosis , instable diabetes mellitus Lack suitability trial : Subjects seasonal asthma asthma season Infectious disease upper airway within 2 week prior study within 4 week prior study case use antibiotic Relevant respiratory disorder asthma Clinically significant renal , endocrine , haematological , hepatic , immunological , gastrointestinal , neurological , psychiatric diseases Any chronic disease might influence absorption , metabolism , excretion trial substance Change inhalative glucocorticosteroid dosage / antiasthmatic controller therapy within last 4 week prior study Concomitant systemic treatment glucocorticosteroids Concomitant treatment ßantagonistic drug Need rescue medication within 15 min challenge Concomitant therapy antidepressant neuroleptic Drug alcohol abuse would interfere subject proper completion protocol assignment mentally handicapped subject Smokers within last 6 month smoke history &gt; 10 packyears ( packyear 20 cigarette per day one year equivalent ) Exposure another investigational agent within last 4 week prior one study Noncooperative subject able understand instruction use device Administrative reason : Lack ability willingness give inform consent Lack willingness personal study relate data collect , archive transmit accord protocol Anticipated nonavailability study visit / procedure Personnel involve plan conduct study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>